aid: flexus-biosciences
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/flexus-biosciences.png
name: Flexus Biosciences
description: 'Flexus Biosciences was a South San Francisco / San Carlos, California
  biotechnology company founded in 2013 to develop small-molecule cancer immunotherapies,
  most notably inhibitors of the IDO/TDO immunosuppressive pathway (lead IDO1 program
  F001287). Backed by Kleiner Perkins and The Column Group, it was acquired by Bristol-Myers
  Squibb in February 2015 for up to roughly $1.25 billion (about $800M upfront) to
  expand BMS''s immuno-oncology pipeline. The company no longer operates independently;
  its domain redirects to the Bristol-Myers Squibb acquisition announcement. It publishes
  no public developer portal, documentation, or API, so this profile carries company
  identity only and no technical API artifacts.'
url: https://raw.githubusercontent.com/api-evangelist/flexus-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- kleiner-perkins
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: bristol-myers-squibb
x-acquired-date: '2015-02'
x-acquisition-announcement: https://news.bms.com/press-release/rd-news/bristol-myers-squibb-expand-its-immuno-oncology-pipeline-agreement-acquire-fle/
x-no-api-surface: true
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Healthcare
- Biotechnology
- Pharmaceuticals
- Immuno-Oncology
- Cancer
- Drug Discovery
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence